- Issue: Over $4 billion paid, continue to represent heart valve surgery patients
For over a decade, Lieff Cabraser has successfully represented patients who took the diet drugs known as fen-phen and suffered serious injuries, including heart valve injuries or developed pulmonary hypertension. We have represented over 2,000 persons who suffered valvular heart disease, pulmonary hypertension, or other problems (such as needing echocardiogram screening for damage) due to and/or following exposure to Fen-Phen and obtained more than $350 million in total for clients in individual cases and/or claims.
Fen Phen Settlement Update from Lieff Cabraser Attorney Fabrice N. Vincent
Additional Compensation Available to "Green Forms" Claimants Until 2015
If you suffered valvular heart disease due to Fen Phen and received compensation under the Diet Drugs Settlement, you may be entitled to additional compensation.
For example, if you had heart disease at Level 1 or Level 2 under the settlement and now require heart valve surgery, you may submit a new claim by using the form below and could be eligible for a recovery of several hundred thousand dollars.
The deadline to submit new claims varies. December 31, 2011 was a deadline applicable to many class members and that deadline only required those class members to have suffered a Qualifying Condition (like heart valve surgery, or death from valve problems) by 12/31/2011, and the Trust's deadline gave those class members up to four additional years to timely file the related claim (under CAP 16). For other patients, like patients who opted out of the 7th amendment, deadlines are further out and those claimants' final deadline to file a claim is December 31, 2015.
Our work on the Fen Phen (Diet Drugs) Litigation and Settlement
Lieff Cabraser represents individuals pursuing personal injury claims due to injuries from the "Fen-Phen" diet drugs fenfluramine (sold as Pondimin) and/or dexfenfluramine (sold as Redux). We served as counsel for the plaintiff that filed the first nationwide class action lawsuit against the diet drug manufacturers alleging that they had failed to adequately warn physicians and consumers of risks associated with the drugs.
Since the recall was announced in 1997, Lieff Cabraser has represented over 500 persons in individual actions who have suffered heart and/or lung damage, most often consisting of cardiac valve damage and/or Primary Pulmonary Hypertension (PPH) or Pulmonary Arterial Hypertension (PAH), after ingesting Pondimin or Redux.
In In re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.), the Court appointed Elizabeth J. Cabraser to the Plaintiffs' Management Committee which organized and directed the Fen-Phen diet drugs litigation filed across the nation in federal courts. In August 2000, the Court approved a $4.75 billion settlement offering both medical monitoring relief for persons exposed to the drug and compensation for persons with qualifying damage. Lieff Cabraser also served on the Plaintiffs' Executive Committee in the California Coordinated Proceedings in California state court, and as class counsel in the State of Washington certified medical monitoring action.
Phen-Fen, Pondimin, and Redux are registered trademarks of American Home Products. The use of these trademarks is solely for product identification and informational purposes. American Home Products is not affiliated with this website, and American Home Products has no affiliation with Lieff Cabraser Heimann & Bernstein, LLP. Nothing on this site has been authorized or approved by American Home Products.